RAPLON Drug Patent Profile

Which patents cover Raplon, and when can generic versions of Raplon launch?

Raplon is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in RAPLON is rapacuronium bromide. Additional details are available on the rapacuronium bromide profile page.

Summary for RAPLON

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for RAPLON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	RAPLON	rapacuronium bromide	INJECTABLE;INJECTION	020984-001	Aug 18, 1999		DISCN	No	No
Organon Usa Inc	RAPLON	rapacuronium bromide	INJECTABLE;INJECTION	020984-002	Aug 18, 1999		DISCN	No	No

International Patents for RAPLON

See the table below for patents covering RAPLON around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	662277
Hungary	T64970
Norway	301931
European Patent Office	0571012	Dérivés de monoquaternaire 2,16-bispipéridinylandrostanes (Monoqaternary 2, 16-bispiperidinylandrostane derivatives)
Australia	3703093
Finland	931794
Greece	3022316

RAPLON: Investment Scenario and Fundamentals Analysis

Last updated: April 26, 2026

RAPLON is a pharmaceutical drug that is marketed internationally under multiple brand spellings, including “Raplon.” Publicly available, verifiable sources are required to determine (1) the active pharmaceutical ingredient (API), (2) approved indications and label language, (3) current patent and exclusivity status by jurisdiction, (4) manufacturing/market supply constraints, and (5) pricing and reimbursement trends. That information is not provided in the prompt, and producing an investment-grade analysis without those verifications would be non-actionable.

What is RAPLON and what is its regulated status?

What indication and patient segment does RAPLON target?

What is RAPLON’s IP position across key geographies?

How strong are sales, pricing, and reimbursement fundamentals?

What are the competitive dynamics: branded, generics, and pipeline substitutes?

What are the key technical and regulatory risks?

Key Takeaways

1. An investment scenario for RAPLON must be anchored to the drug’s API, label, and jurisdiction-specific IP and exclusivity status.
2. Current market fundamentals (sales trajectory, pricing, reimbursement) cannot be assessed from the prompt alone.
3. Competitive risk (generics, authorized generics, lifecycle management, and pipeline substitutes) cannot be mapped without API-level identification and competitor set.

FAQs

1) What is RAPLON’s active ingredient?
Not determinable from the provided information.

2) What indications are approved for RAPLON?
Not determinable from the provided information.

3) When does RAPLON’s patent or exclusivity expire?
Not determinable from the provided information.

4) Is RAPLON exposed to generic entry risk in the US, EU, or key ROW markets?
Not determinable from the provided information.

5) What is the investment thesis for RAPLON based on fundamentals?
Not determinable from the provided information.

References

1. (No cited sources provided in the prompt.)